Blue Water Vaccines (BWV) Announces Exercise of Warrants, New $2.7M Private Warrant Placement Aug 1, 2023 08:01AM
Blue Water Vaccines (BWV) Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform Jun 28, 2023 07:55AM
Blue Water Vaccines (BWV) Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio Jun 21, 2023 07:33AM
Blue Water Vaccines (BWV) Acquires Six FDA-Approved Drugs Across Various Treatment Areas Jun 14, 2023 07:33AM
Blue Water Vaccines (BWV) Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates Feb 1, 2023 09:15AM


Nov 21, 2022 08:01AM Blue Water Vaccines (BWV) Announces Exclusive, Global License Agreement for Chlamydia Vaccine Candidate
Nov 10, 2022 08:48AM Blue Water Vaccines (BWV) Announces 5M Share Buyback, Reports Q3
Aug 17, 2022 08:46AM Blue Water Vaccines (BWV) Announces Exploration of Its Virus-Like Particle Platform for Use in Monkeypox Vaccine Candidate
Jul 20, 2022 02:01PM Blue Water Vaccines (BWV) Announces Signing of Sponsored Research Agreement with Cincinnati Children’s Hospital Medical Center for S&P Vaccine Platform Development
May 13, 2022 05:19PM Blue Water Vaccines (BWV) Reports Q1 Net Loss of $2.1M
Mar 22, 2022 07:05AM blue water vaccines (BWV) Reports Publication Supporting Novel S&P Vaccine Platform Versatility